ReviewJournal of medicinal chemistry2024
Chirality of New Drug Approvals (2013-2022): Trends and Perspectives.
Review in Journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed.
- Unleashing the power of DNA-encoded libraries for challenging targets in drug discovery.Pharmaceutical science advances · 2026Review
- Green chiral HPLC method on a polysaccharide column under hydro-organic conditions for the determination of Levobupivacaine, Ropivacaine, and their enantiomeric impurities.BMC chemistry · 2026Article
- Capillary Electrophoretic Enantioseparation of Profens: Advances in Chiral Selectors, Separation Strategies, and Analytical Applications.Molecules (Basel, Switzerland) · 2026Review
- Rethinking Chiral Decision-Making in Pharmaceutical Analysis: The Emerging Role of Artificial Intelligence.Chirality · 2026Review
- Chiral Analysis for High-Throughput Reaction Screening: Recent Advances in Accelerating Asymmetric Catalysis Discovery.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Review
- Synthesis of Non-Steroidal Anti-Inflammatory Drugs Pelubiprofen, Loxoprofen, and Carprofen Through Batch and Continuous-Flow Photo-Favorskii Rearrangement.Molecules (Basel, Switzerland) · 2026Article
- Three privileged scaffolds, one pipeline: chalcones, pyrazolines and pyrazoles in drug discovery and fluorescent sensing.RSC medicinal chemistry · 2026Review
- Planar Chirality Directs Enantiospecific Diastereoselectivity in Isocyanide-Based Multicomponent Reactions.ACS organic & inorganic Au · 2026Article
- Chiral Resolution of Aspartic Acid Racemate by Single Crystallization With Phenylalanine as Additive.Chirality · 2026Article
- Cyclodextrins as Chiral Selectors in Capillary Electrophoresis-Recent Developments in Understanding Analyte Complexation and Applications in Pharmaceutical Analysis.Electrophoresis · 2026Review
- Article
- Catalytic asymmetric synthesis of inherently chiral tricyclic diazepinones: Access to (+)-telenzepine.Science advances · 2026Article
- Direct Stereospecific Deoxyamination of Alcohols Enabled by Li-Mediated SuFEx.Organic letters · 2026Article
- A machine learning-based workflow for transaminase selection.Chemical science · 2026Article
- Chiral (Stereoselective) Drugs, Asymmetric Synthesis, and Racemic Resolution Methods.Chirality · 2026Review
- Article
- TCM-Derived Small Molecules Targeting Metabolic Vulnerabilities in NSCLC: Ferroptosis-Centered Mechanisms and Emerging Cuproptosis- and Disulfidptosis-Related Vulnerabilities.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Peripheral editing of polyols to chiral alkanes.Nature communications · 2026Article
- Stereoselective Biotransformation: Transfer of Learning to Advance Drug Metabolism and Biocatalysis.Angewandte Chemie (International ed. in English) · 2026Review
- Effect of Stereochemistry on the Antiplasmodial Activity and Metabolomic Profile of Novel Tadalafil Analogues.ACS medicinal chemistry letters · 2026Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many drugs are chiral with their chirality determining their biological interactions, safety, and efficacy. Since the 1980s, there has been a regulatory preference to bring single enantiomer to market. This perspective discusses trends related to chirality that have developed in the past decade (2013-2022) of new drug approvals. The EMA has not approved a racemate since 2016, while the average for the FDA is one per year from 2013 to 2022. These 10 include drugs which have been previously marketed elsewhere for several decades, analogues of pre-existing drugs, or drugs where the undefined stereocenter does not play a role in therapeutic activity. Two chiral switches were identified which were both combined with drug repurposing. This combination strategy has the potential to produce therapeutically valuable drugs in a faster time frame. Two class III atropisomers displaying axial chirality were approved between 2013 and 2022, one as a racemate and one as a single enantiomer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.